245 related articles for article (PubMed ID: 20021346)
1. Histamine H3-receptor inverse agonists as novel antipsychotics.
Ito C
Cent Nerv Syst Agents Med Chem; 2009 Jun; 9(2):132-6. PubMed ID: 20021346
[TBL] [Abstract][Full Text] [Related]
2. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
4. Role of the Histamine H
Schlicker E; Kathmann M
Handb Exp Pharmacol; 2017; 241():277-299. PubMed ID: 27787717
[TBL] [Abstract][Full Text] [Related]
5. [The histamine H3 receptor: a new target for the treatment of arousal and cognitive disorders].
Arrang JM
Ann Pharm Fr; 2007 Jul; 65(4):275-84. PubMed ID: 17652997
[TBL] [Abstract][Full Text] [Related]
6. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?
Deng C; Weston-Green K; Huang XF
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):1-4. PubMed ID: 19922755
[TBL] [Abstract][Full Text] [Related]
7. Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.
Patnaik R; Sharma A; Skaper SD; Muresanu DF; Lafuente JV; Castellani RJ; Nozari A; Sharma HS
Mol Neurobiol; 2018 Jan; 55(1):312-321. PubMed ID: 28861757
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia.
Brown JW; Whitehead CA; Basso AM; Rueter LE; Zhang M
Int J Neuropsychopharmacol; 2013 May; 16(4):889-904. PubMed ID: 22906530
[TBL] [Abstract][Full Text] [Related]
9. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
Lim HD; van Rijn RM; Ling P; Bakker RA; Thurmond RL; Leurs R
J Pharmacol Exp Ther; 2005 Sep; 314(3):1310-21. PubMed ID: 15947036
[TBL] [Abstract][Full Text] [Related]
11. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
[TBL] [Abstract][Full Text] [Related]
12. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
[TBL] [Abstract][Full Text] [Related]
13. Histamine H
Ghamari N; Zarei O; Arias-Montaño JA; Reiner D; Dastmalchi S; Stark H; Hamzeh-Mivehroud M
Pharmacol Ther; 2019 Aug; 200():69-84. PubMed ID: 31028835
[TBL] [Abstract][Full Text] [Related]
14. A Novel Potent and Selective Histamine H
Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats.
Blandina P; Giorgetti M; Bartolini L; Cecchi M; Timmerman H; Leurs R; Pepeu G; Giovannini MG
Br J Pharmacol; 1996 Dec; 119(8):1656-64. PubMed ID: 8982515
[TBL] [Abstract][Full Text] [Related]
16. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.
Esbenshade TA; Browman KE; Bitner RS; Strakhova M; Cowart MD; Brioni JD
Br J Pharmacol; 2008 Jul; 154(6):1166-81. PubMed ID: 18469850
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist.
Panayi F; Sors A; Bert L; Martin B; Rollin-Jego G; Billiras R; Carrié I; Albinet K; Danober L; Rogez N; Thomas JY; Pira L; Bertaina-Anglade V; Lestage P
Eur J Pharmacol; 2017 May; 803():1-10. PubMed ID: 28315340
[TBL] [Abstract][Full Text] [Related]
18. Histamine and schizophrenia.
Arrang JM
Int Rev Neurobiol; 2007; 78():247-87. PubMed ID: 17349864
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors.
Sors A; Panayi F; Bert L; Favale D; Nosjean O; Audinot V; Arrang JM; Buisson B; Steidl E; Delbos JM; Huhtala T; Kontkanen O; Chollet AM; Casara P; Lestage P
Eur J Pharmacol; 2017 May; 803():11-23. PubMed ID: 28336400
[TBL] [Abstract][Full Text] [Related]
20. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
